{"id":32314,"date":"2017-04-12T12:00:00","date_gmt":"2017-04-12T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/"},"modified":"2017-04-12T12:00:00","modified_gmt":"2017-04-12T12:00:00","slug":"neuartige-entwicklungen-bei-biologika-fuer-crswnp","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/de\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/","title":{"rendered":"Neuartige Entwicklungen bei Biologika f\u00fcr CRSwNP"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--1391 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h2>Rhinology Future Debates 2016<\/h2>\n<p>Prof. Claire Hopkins (UK) moderiert diese Sitzung zur Diskussion \u00fcber neuartige monoklonale Antik\u00f6rper bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP). Die in dieser Debatte er\u00f6rterten Punkte beziehen sich auf den ungedeckten Bedarf, die Herausforderung neuer Behandlungen, Fragen an das Gremium sowie Dupilumab bei Typ-2-Entz\u00fcndungen. <\/p>\n<h3>Podiumsteilnehmende<\/h3>\n<p>Prof. Claus Bachert, Prof. Manuel Bernal, Prof. Wytske Fokkens und Prof. Peter Hellings.<\/p>\n<\/div><\/div>\n<\/p><\/div>\n<p>,  <\/p>\n<div class=\"paragraph paragraph--text-columns paragraph-id--1392 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<div class=\"video-container\">\n<center><iframe width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/D9PBHqQU9GM?rel=0\" title=\"YouTube-Videoplayer\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><\/center>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Rhinology Future Debates 2016 Prof. Claire Hopkins (UK) moderiert diese Sitzung zur Diskussion \u00fcber neuartige monoklonale Antik\u00f6rper bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP). Die in dieser Debatte er\u00f6rterten Punkte beziehen sich auf den ungedeckten Bedarf, die Herausforderung neuer Behandlungen, Fragen an das Gremium sowie Dupilumab bei Typ-2-Entz\u00fcndungen. Podiumsteilnehmende Prof. Claus Bachert, Prof. Manuel Bernal, Prof. Wytske Fokkens und Prof. Peter Hellings. ,<\/p>\n","protected":false},"author":1,"featured_media":32334,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[182],"tags":[184,185,186,157,183],"class_list":["post-32314","news","type-news","status-publish","has-post-thumbnail","hentry","category-rhinology-future-debates","tag-debatten","tag-rhinology-future-debates","tag-biologika","tag-chronische-rhinosinusitis-crs","tag-rhinologie"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Neuartige Entwicklungen bei Biologika f\u00fcr CRSwNP - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/de\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuartige Entwicklungen bei Biologika f\u00fcr CRSwNP\" \/>\n<meta property=\"og:description\" content=\"Rhinology Future Debates 2016 Prof. Claire Hopkins (UK) moderiert diese Sitzung zur Diskussion \u00fcber neuartige monoklonale Antik\u00f6rper bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP). Die in dieser Debatte er\u00f6rterten Punkte beziehen sich auf den ungedeckten Bedarf, die Herausforderung neuer Behandlungen, Fragen an das Gremium sowie Dupilumab bei Typ-2-Entz\u00fcndungen. Podiumsteilnehmende Prof. Claus Bachert, Prof. Manuel Bernal, Prof. Wytske Fokkens und Prof. Peter Hellings. ,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/de\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\\\/\",\"name\":\"Neuartige Entwicklungen bei Biologika f\u00fcr CRSwNP - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg\",\"datePublished\":\"2017-04-12T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\\\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/waehlen-sie-ihren-weg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Neuartige Entwicklungen bei Biologika f\u00fcr CRSwNP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Neuartige Entwicklungen bei Biologika f\u00fcr CRSwNP - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/de\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/","og_locale":"de_DE","og_type":"article","og_title":"Neuartige Entwicklungen bei Biologika f\u00fcr CRSwNP","og_description":"Rhinology Future Debates 2016 Prof. Claire Hopkins (UK) moderiert diese Sitzung zur Diskussion \u00fcber neuartige monoklonale Antik\u00f6rper bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP). Die in dieser Debatte er\u00f6rterten Punkte beziehen sich auf den ungedeckten Bedarf, die Herausforderung neuer Behandlungen, Fragen an das Gremium sowie Dupilumab bei Typ-2-Entz\u00fcndungen. Podiumsteilnehmende Prof. Claus Bachert, Prof. Manuel Bernal, Prof. Wytske Fokkens und Prof. Peter Hellings. ,","og_url":"https:\/\/www.euforea.org\/de\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","twitter_card":"summary_large_image","twitter_site":"@euforea","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/de\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/","url":"https:\/\/www.euforea.org\/de\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/","name":"Neuartige Entwicklungen bei Biologika f\u00fcr CRSwNP - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/de\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/de\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg","datePublished":"2017-04-12T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/de\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/de\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.euforea.org\/de\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/de\/news\/neuartige-entwicklungen-bei-biologika-fuer-crswnp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.euforea.org\/de\/waehlen-sie-ihren-weg\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/de\/news\/"},{"@type":"ListItem","position":3,"name":"Neuartige Entwicklungen bei Biologika f\u00fcr CRSwNP"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/de\/#website","url":"https:\/\/www.euforea.org\/de\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/de\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/de\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.euforea.org\/de\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/news\/32314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/comments?post=32314"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/news\/32314\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/media\/32334"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/media?parent=32314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/categories?post=32314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/tags?post=32314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}